Vida Ventures

Congratulations to #AvalynPharma on its successful upsized IPO (NASDAQ: AVLN)! Proud to support the team as they work to establish a new standard of care for patients with pulmonary fibrosis. Kudos to the entire Avalyn team on this exciting milestone. bit.ly/4eheRmy $AVLN #VidaPortfolio #IPO #PulmonaryFibrosis

Congratulations to #AktisOncology on its successful IPO and entry into the public markets and excited for what’s ahead. Proud to have partnered with Aktis since co-leading its Series A—supporting the company from discovery through IPO. Vida is one of Aktis’s largest shareholders, with our own Helen Kim serving on the Board since 2021, and Brian Goodman helping build the company from day one. bit.ly/3LzM1lk #IPO #Biotech #Radiopharmaceuticals #VidaVentures $AKTS

Congratulations to the @HaldaTx team and @JNJNews on this historic milestone. A powerful validation of the RIPTAC™ platform and its potential to impact patients with prostate cancer and solid tumors. Learn more: bit.ly/4822VjA

Congrats to our portfolio company @lb_pharma on its IPO, the first biotech in 6 months. A major step forward for #mentalhealth and #schizophrenia. $LBRX bit.ly/42k22Ru

Delighted to share that Vida Principal, Chris Weyrer, MD, PhD, will join the Investor Panel at the 8th Neuropsychiatric Drug Development Summit in Boston, along with fellow industry experts. ter.li/42ap36 Panel: 9/11/25, 9AM ET

Thrilled to celebrate @capstantx as their acquisition by @abbvie is complete! Excited to see them join forces to advance life-changing therapies. Read more: bit.ly/47zmBwH

Exciting news! @HaldaTx received FDA Fast Track designation for their lead candidate, HLD-0915, for patients with metastatic castration-resistant prostate cancer (mCRPC). Learn more: bit.ly/3Hncr7V #VidaPortfolio #HoldandKillCancer

Congrats to the Capstan team and @PennMedicine’s scientific luminaries on a defining moment for cell therapy - Capstan’s $2.1B acquisition by @AbbVie! Proud to have backed this bold vision from seed. Excited to see AbbVie advance this groundbreaking science. #biotech #celltherapy #immunology #oncology #Vida

Congrats to the @capstantx team on dosing the first participants in their Phase 1 trial of CPTX2309—a first-in-class in vivo CAR-T therapy for autoimmune disease. Proud to support Capstan as they pioneer a new class of treatments for patients in need. bit.ly/3ZZUMcl

Congrats to the @antares_rx team on their launch and $177M Series A! We're proud to support this mission to bring first-in-class precision medicines to patients in need. #DoingWellByDoingGood Learn more: bit.ly/3FSPt7G

Congrats to the #AktisOncology team on the advancement of AKY-1189, a first-in-class Nectin-4-targeting radiopharmaceutical, into the clinic —an exciting step forward to address high unmet need patient populations. Learn more: bit.ly/3Sp82Dm

Big milestone for @VigilNeuro—announcing an agreement to join @Sanofi. A strong validation of the team’s vision and potential of TREM2 agonist therapies for patients with Alzheimer's disease. Congrats to the Vigil team! bit.ly/4kcOpuv

#ASCO2025 updates from @VolastraTx & @HaldaTx, two #VidaPortfolio companies advancing novel cancer therapies: Volastra will present on June 2 | 8AM CT | Room S406 | bit.ly/44MvuBO Halda will present on June 2 | 9AM–12PM CT | Poster #311b | bit.ly/43bOZCF

Today, @HaldaTx welcomes Dr. Eyal Attar as Chief Medical Officer. His expertise will help advance RIPTAC cancer therapies to patients with solid tumors & other serious diseases. Learn more: bit.ly/4ilVvuJ #VidaPortfolio #HoldandKillCancer

Thrilled to announce the appointment of Matt Cohen, MD, MBA & Brian Goodman, PhD as Managing Directors at Vida Ventures. Excited for this next chapter! endpts.com/arie-belldegru… #Biotech #HealthcareInnovation #VidaVentures

@HaldaTx has initiated the first-in-human Phase 1/2 clinical trial for HLD-0915, a RIPTAC™ therapeutic, aimed at treating metastatic castration-resistant prostate cancer (mCRPC). Congratulations, Halda team! Learn more: bit.ly/4if1xh1 #HoldandKillCancer #VidaPortfolio

Eli Lilly’s chief scientific officer said the company purchased a cancer drug from the startup Scorpion Therapeutics because it "checked all the boxes." trib.al/rDRdMyk

@EliLillyandCo has agreed to acquire @ScorpionTx in a deal worth up to $2.5 billion. As a founding investor, we are proud to have been on this journey with the Scorpion team and look forward to what this will mean for patients in need of new options. #JPM2025 #precisiononcology

Congrats, @HaldaTx, on the appointment of Chris Schade as President and CEO! Chris’ 20 years of pharma and biotech industry experience will be an incredible asset to the company as they leverage the RIPTAC platform to improve outcomes for cancer patients. bit.ly/4eHyXTV